Indocid

Selected form

Indometacin

Method of action: Analgesic, Analgetic, Anti-Inflammatory, Antipyretic, Decongestant, Decongestant Local, Desensitizing, Local Anesthetic, Ophthalmologicals, Pain Reliever

Treatment option: Ankylosing Spondylitis, Arthritis,Osteoarthritis, Pain, Pain, Back, Osteoarthritis, Edema, Gout, Gouty Arthritis, Rheumatoid Arthritis, Spondylitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Indocid

Property	Description
Active Ingredient	Indometacin (Indomethacin)
Pharmacological Class	Nonsteroidal Anti-Inflammatory Drug (NSAID)
Form	Capsules, oral suspension, suppository, powder for injection
Origin	Synthetic (indole-acetic acid derivative)
General Purpose	Symptomatic relief of pain, inflammation, and fever

Indocid is a commercial brand name for the prescription-only pharmaceutical agent whose active ingredient is Indometacin (or Indomethacin). It is classified as a potent member of the Nonsteroidal Anti-Inflammatory Drug (NSAID) class. Chemically, Indometacin is a synthetic compound derived from indole-acetic acid, which defines its structure and potent pharmacological profile.

What Type of Medicine is Indocid?

Indocid is an analgesic, anti-inflammatory, and antipyretic agent that provides symptomatic relief by interrupting the body’s inflammatory cascade. The drug is clinically recognized for its potent, nonselective inhibition of Cyclooxygenase (COX) enzymes. This means the medicine works by effectively blocking the signals in the body that cause pain, swelling, and heat.

This therapeutic function is primarily achieved through its ability to block prostaglandin synthesis, reducing the chemical messengers that promote pain, inflammation, and fever throughout the body. The specific potency of this indole derivative often positions it for scenarios where severe musculoskeletal discomfort needs management, as opposed to milder, short-term pain.

Composition, Forms, and General Therapeutic Purpose

Indocid is supplied as a single-ingredient product in various dosage forms, including oral capsules and oral suspension, as well as suppositories for rectal administration. This range, particularly the availability of the rectal form, provides therapeutic flexibility for patients who may not tolerate oral medication.

The general therapeutic purpose of Indocid is limited to the reduction of pain, the suppression of inflammation, and the regulation of fever. The drug's established use for symptomatic relief across various inflammatory conditions is recognized as a tool for when a strong effect is required.

What side effects are possible with Indocid?

Possible Side Effects and Safety Information

The safety profile of Indocid (Indometacin) is officially categorized by potential adverse reactions across several major organ systems, consistent with regulatory classifications for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).

Frequency-Classified Adverse Reactions

The most frequently reported effects, generally classified as common in regulatory documents, involve the central nervous system and the gastrointestinal tract. These include headache, dizziness, dyspepsia, nausea, and peripheral oedema (fluid retention). Rarer adverse events may affect the blood and lymphatic system.

Serious Adverse Reaction Risks

Official prescribing information highlights the potential for serious, sometimes fatal, risks that may occur at any time during treatment. These serious risks include major Cardiovascular Thrombotic Events such as Myocardial Infarction (heart attack) and Stroke. Additionally, the drug carries a risk for severe Gastrointestinal Adverse Events, including ulceration, bleeding, and perforation of the stomach or intestine. Rare but serious reactions also involve risks to the liver (hepatotoxicity) and kidneys (acute renal failure).

Population and Duration Safety Constraints

Regulatory documents specify that the risk of serious adverse events often increases with the duration of use and is typically higher in older adults. The medication is subject to official restrictions, including being contraindicated in patients with a history of aspirin-related allergies or in the setting of coronary artery bypass graft (CABG) surgery. Furthermore, use is generally avoided in late pregnancy due to the risk of premature closure of the fetal ductus arteriosus.

Overdose and Emergency Response

Indocid (Indometacin) overdose may present with a spectrum of acute clinical manifestations involving the central nervous system (CNS) and the gastrointestinal (GI) tract. Documented symptoms often include severe headache, confusion, unusual drowsiness, tinnitus, and signs of GI distress such as nausea, vomiting (sometimes with blood), and diarrhea. A severe overdose can rapidly escalate to life-threatening clinical outcomes. Regulatory documents list serious complications including seizures, coma, the potential for massive internal bleeding, and acute renal failure. Given these risks, seeking immediate medical help is required upon any suspected overdose, and Poison Control should be contacted for instructions. Emergency services should be contacted if the individual exhibits life-threatening symptoms such as loss of consciousness or signs of severe hemorrhage. Management is strictly symptomatic and supportive, as no specific antidote for Indometacin is known. Procedures described in official labeling may include gastric lavage, administration of activated charcoal, and the provision of IV fluids. Hospital monitoring of vital signs is necessary, and diagnostic tests such as ECG and endoscopy may be performed. Elderly or debilitated patients are noted to have an increased risk of severe or fatal GI events.

Therapeutic Uses of Indocid

What Indocid Treats: Main Uses and Benefits

Indocid is an established Nonsteroidal Anti-Inflammatory Drug (NSAID) whose therapeutic application is centered on providing support from severe inflammatory symptoms.

The medication is commonly used to help manage symptoms related to inflammatory and arthritic conditions. This includes chronic disorders like Rheumatoid Arthritis, Ankylosing Spondylitis, and moderate to severe Osteoarthritis, as well as acute flares such as acute gouty arthritis and localized inflammation like acute painful shoulder (bursitis/tendinitis).

This supportive therapeutic benefit helps patients cope more steadily when groups of symptoms appear suddenly or fluctuate. When discussing therapeutic goals for symptomatic support:

The primary purpose of symptomatic relief is to help patients cope more steadily with difficult episodes.

In chronic care, Indocid is applied to ease symptom clusters that include deep joint pain, persistent swelling, and symptoms that interfere with daily functioning, supporting the patient with maintaining functional stability. In acute scenarios, it assists with managing the severity of highly distressing manifestations, offering relief commonly used when short-term symptomatic assistance is needed. Furthermore, in specialized care, the medication is generally used to offer supportive therapeutic benefit for a Patent Ductus Arteriosus (PDA) in premature newborns.

Therapeutic Focus: Relief for Inflammatory Symptoms
Indocid is relevant for easing symptoms related to inflammatory or irritative states, contributing to improved comfort during periods of heightened physical discomfort.

Eligibility and Restrictions for Use

Eligibility for Indocid (Indometacin) Use

Official regulatory documents define strict population eligibility for Indocid, a potent nonsteroidal anti-inflammatory drug (NSAID). Use is contraindicated for patients with a known hypersensitivity to indometacin or a history of allergic reactions (e.g., asthma, urticaria) after taking aspirin or other NSAIDs. The medicine must not be used for peri-operative pain management in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Use is highly restricted for specific physiological and age groups:

Population Group	Regulatory Status
Pregnancy (starting at 30 weeks gestation)	Contraindicated
Children (under 14 years, oral/rectal)	Safety/Efficacy Not Established

For adults, Indocid must be avoided in cases of advanced renal disease or severe heart failure unless physician-determined benefits outweigh the risks. Additionally, the suppository form is contraindicated for individuals with a history of proctitis or rectal bleeding. Older adults may be more susceptible to effects and require special caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation details specific interaction patterns for Indocid (Indometacin) with other medicines and substances. These interactions are classified based on their documented outcomes, focusing on exposure modification and pharmacodynamic risk amplification.

Interacting Agents and Classes	Documented Interaction Effect
Anticoagulants/Antiplatelet Agents (e.g., Warfarin, SSRIs/SNRIs)	Increases the risk of bleeding and gastrointestinal adverse events.
Lithium, Digoxin	Indocid may reduce the renal clearance of these agents, leading to increased plasma concentrations and exposure.
Methotrexate	Co-administration may decrease the elimination of Methotrexate, potentially increasing systemic exposure.
Antihypertensives (ACE Inhibitors, ARBs, Diuretics)	May diminish the antihypertensive or natriuretic effect of these co-administered medicines.
Other NSAIDs/Analgesic Aspirin	Co-administration is generally not recommended due to increased systemic risk.

Specific usage constraints are documented for Indocid. Use is formally contraindicated for the treatment of peri-operative pain in the context of Coronary Artery Bypass Graft (CABG) surgery. Additionally, concurrent ingestion of Alcohol is documented to significantly increase the risk of gastrointestinal mucosal bleeding and ulceration. A higher risk of deterioration of renal function is noted when Indocid is co-administered with ACE Inhibitors or ARBs in populations such as the elderly, the volume-depleted, or those with existing renal impairment.

Mechanism of Action

Inhibiting the Prostaglandin Synthesis Pathway

Indocid (Indomethacin) functions by non-selectively inhibiting the Cyclooxygenase (COX) enzyme system, affecting both the COX-1 and COX-2 isoforms. This targeted enzyme interaction initiates a mechanistic cascade that prevents the formation of prostaglandins, which are lipid mediators synthesized within the eicosanoid pathway. The subsequent suppression of prostaglandin synthesis alters the concentration of these eicosanoids within localized physiological systems.

Modulating Signaling and Cellular Processes

This core mechanism influences signaling dynamics across both peripheral tissue sites and central regulatory systems involved in hypothalamic signaling and sensory transduction. The resulting alteration in mediator levels influences the signaling sequence within inflammatory pathways. Additionally, Indocid is associated with engaging secondary mechanisms, including influencing cellular components such as the migration of certain immune cells. It also contributes to modifying early molecular steps by affecting the availability of the precursor molecule, arachidonic acid, thereby restricting the starting material for the entire cascade.

Dosage and Administration Information

How to Use Indocid (Indomethacin)

Indocid's administration follows established protocols regarding its form, route, and dosage schedule, emphasizing the use of the lowest effective dose for the shortest necessary duration.

Administration Routes and Forms

Indomethacin is provided for three primary routes of administration: Oral (immediate-release capsules, extended-release capsules, and suspension), Rectal (suppositories), and Intravenous (IV). The IV formulation is restricted to highly specialized care for the treatment of Patent Ductus Arteriosus in premature infants, with dosing based on the infant’s weight and postnatal age.

Official Dosing and Timing Principles

Usage Context	Key Dosing Instruction	Administration Condition
Chronic Conditions (e.g., Arthritis)	Initial oral dose typically starts at 25 mg two or three times daily, with dose adjustments (titration) occurring at weekly intervals. The maximum recommended daily dose for immediate-release forms is 200 mg.	Oral forms should be taken with food, milk, or an antacid to mitigate potential gastrointestinal upset.
Acute Conditions (e.g., Gout Flare)	Oral dosing often begins at 50 mg three times a day. Upon relief of the acute episode, the medicine is intended to be reduced to complete cessation.	The total daily dose is divided throughout the day, or a portion, up to 100 mg, may be administered at bedtime.

Procedural Handling

The Extended-Release capsules must be swallowed whole and must not be crushed, broken, or chewed, as this alters the intended drug release profile. The oral suspension requires thorough shaking before use. For IV administration, the powder must be reconstituted using a preservative-free diluent and infused over 20 to 30 minutes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Indocid (Indometacin)

Research Evidence for Chronic Inflammatory Conditions

This section will summarize the available evidence from clinical trials and observational studies that have investigated the medicine for conditions characterized by fluctuating or episodic manifestations, such as Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis. It will outline the types of studies conducted and the specific symptomatic and functional outcomes measured in these populations.

For Rheumatoid Arthritis, research was conducted using short-term Randomized Controlled Trials (RCTs) and longer observational studies. Research describes patterns observed in the studies related to changes in symptom measurements, including pain scores and morning stiffness. The available research does not characterize the effect of the medicine on the long-term progression of the underlying disease.

For Osteoarthritis, the evidence provides limited insight into the monitoring of long-term outcomes related to joint structure or the maintenance of physical function over many years. Research for Ankylosing Spondylitis utilized RCTs to examine outcomes related to spinal pain and stiffness, though evidence comparing the drug to modern biologic therapies may be restricted.

Studies on Acute Pain and Inflammation

This section focuses on the research supporting the use of the medicine for short-term, acute inflammatory episodes, including Acute Gouty Arthritis and Acute Painful Shoulder (Bursitis/Tendinitis). It will detail the study designs used to measure the rapid onset of symptomatic changes in these acute clinical settings.

In Acute Gouty Arthritis, the evidence base includes RCTs and meta-analyses. Findings describe patterns observed in the studies related to changes in symptom intensity and changes in acute inflammatory signs. Research is highly focused on acute symptom resolution, offering limited data on preventing future gout flares.

For Acute Painful Shoulder, research utilized short-term RCTs to evaluate the medicine. This research provides insight into short-term changes, but the data is primarily short-term, offering limited information on whether changes in symptoms were sustained or how recurrence was monitored.

Evidence in Specialized Medical Contexts

This part of the overview will address the unique body of research related to specialized uses, specifically studies evaluating Patent Ductus Arteriosus (PDA) in premature infants and research on prophylaxis for Heterotopic Ossification (HO) following certain procedures.

For PDA in premature infants, a substantial body of research was conducted, focusing on the monitoring of ductus arteriosus patency, the need for surgical ligation, and the incidence of severe cerebral hemorrhage (IVH). Research findings on long-term neurodevelopmental outcomes across all prophylactic studies have shown some inconsistencies.

Research for Prophylaxis for Heterotopic Ossification (HO) involved RCTs and systematic reviews, tracking the monitoring of HO formation patterns after orthopedic procedures in adults. Sample sizes were modest in some analyses, and the optimal duration of treatment remains a research question.

Areas of Uncertainty and Research Gaps

This section clarifies what the existing scientific literature and regulatory documents identify as the main unanswered questions.

Across the various indications, a common limitation is that follow-up durations were limited in many controlled trials. This means that while research highlights what is known about short-term relief, long-term effects are not fully established. Furthermore, comparative evidence is lacking in many areas against non-drug interventions or newer therapeutic agents. Research highlights that the findings describe group patterns, not personal outcomes, and that these study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Indocid (FAQ)

Q: What is the main difference between Indocid and ibuprofen or naproxen?

Indocid (indomethacin) is described in regulatory documents as a potent medicine within the non-steroidal anti-inflammatory drug (NSAID) class. Regulatory documentation indicates that it may be associated with a greater potential for certain adverse effects, particularly gastrointestinal issues, compared to some other NSAIDs. Indocid is also a prescription-only medication.

Q: Is Indocid an opioid or a narcotic?

No, Indocid is not classified as an opioid or a narcotic. The active ingredient, indomethacin, belongs to the family of non-steroidal anti-inflammatory drugs (NSAIDs) and is not scheduled by regulatory bodies as a controlled substance and does not carry a risk for physical or psychological dependence.

Q: Is it normal to feel a change in appetite while taking Indocid?

Regulatory documents mention that a loss of appetite, known as anorexia, has been reported as an adverse reaction in clinical experience. While this may not be a frequently reported event, official product information indicates that this symptom has occurred in patients treated with indomethacin.

Q: Can taking Indocid affect my sleep?

Official safety information indicates that Indocid can affect sleep patterns. Adverse reactions reported include both insomnia (difficulty falling or staying asleep) and somnolence (unusual drowsiness or sleepiness). These are central nervous system effects documented in the official labeling.

Q: If I miss a dose of Indocid, what does official guidance say?

Official medication guides include instructions for managing a missed dose. These instructions generally advise that if it is near the time for the next scheduled dose, the patient should skip the missed dose and resume the normal dosing schedule. Furthermore, regulatory guidelines state that a patient should never take two doses at the same time.

Q: What are the common signs of a serious reaction to Indocid?

Official medication guides describe specific signs of serious adverse events that should prompt immediate medical attention. These signs include symptoms related to the heart, such as chest pain, sudden shortness of breath, or weakness. They also describe gastrointestinal issues, such as bloody or tar-like stools, or vomiting blood. The presence of a skin rash, blisters, or fever may also signal a severe reaction.

Q: Can Indocid interact with herbal supplements?

Official regulatory documents detail specific interactions with many prescription drugs, but not all herbal supplements are specifically listed. Official documents generally note that a patient's healthcare team should be informed about all co-administered substances, including herbal and dietary supplements, to assess potential risks.

Q: Is Indocid listed as causing photosensitivity or sun reaction?

Official safety documents warn of the potential for severe skin reactions, such as exfoliative dermatitis or toxic epidermal necrolysis. The advice concerning any rash or severe skin reaction described in official documents is that the medication should be discontinued.

Q: Does Indocid have a potential for dependency?

No. Official regulatory documents indicate that Indocid does not carry a risk for dependency. It is not classified as a controlled substance because its mechanism of action as a non-steroidal anti-inflammatory drug (NSAID) is not associated with physical or psychological reliance.

Q: What is the general regulatory position on taking Indocid while breastfeeding?

According to official product information concerning nursing mothers, indomethacin is known to be excreted in breast milk. Therefore, the use of Indocid is generally not advised in official regulatory documents for women who are currently breastfeeding.

Q: Can Indocid affect blood sugar levels?

Yes, official adverse event reports list that Indocid may affect blood sugar levels. Both hyperglycemia (elevated blood sugar) and glycosuria (the presence of sugar in the urine) are listed as reported adverse reactions in official safety documents.

Q: Can Indocid affect the results of certain lab tests?

Official patient information indicates that Indocid may affect the results of certain laboratory tests. Due to this potential for interference, official documents state that a patient's doctor or laboratory technician should be informed of the medication use.

How should Indocid be stored and disposed of?

How to Store and Dispose of Indocid?

The storage and disposal of Indocid (Indometacin) are governed by official regulatory standards to maintain product stability and safety. Adherence to these requirements is mandatory and is typically dependent on the specific dosage form (capsules, suspension, suppositories).

Official Storage Constraints

Constraint Type	Required Rule
Temperature Range	Capsules must be stored at mathbf20 C to mathbf25 C (Controlled Room Temperature).
Environmental Protection	Suppositories require storage away from light and moisture; the oral suspension must not be frozen.
Container Integrity	Keep the medication in the original container and ensure the cap is tightly closed.

Stability and Safety Rules

For stability, the oral suspension must be discarded 4 weeks after opening. For safety, the medicine must always be stored out of the sight and reach of children.

Mandatory Disposal Instructions

Do not dispose of Indocid via wastewater or household waste. Unused or expired medication must be handled according to local requirements, and patients should consult a pharmacist for official disposal guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.